Effect of Concomitant Medications on Efficacy of Sonidegib 200 Mg Daily in Patients with Locally Advanced Basal Cell Carcinoma: Results of the 42-Month Randomized, Double-Blind BOLT Study

Main Article Content

Richard Dummer
Michael Migden
Nicholas Squittieri
Li Liu
Alexander Guminski
John Lear


Basal Cell Carcinoma, Sonidegib, concomitant medications, efficacy


Abstract not available.


1) Xiang F, et al. JAMA Dermatol. 2014; 150:1063–71

2) Asgari MM, et al. JAMA Dermatol. 2015; 151:976–81

3) Amici JM, et al. Eur J Dermatol. 2015; 25:586–94

4) Lear JT, et al. Br J Cancer. 2014; 111:1476–81

5) Cortes JE, et al. Cancer Treat Rev. 2019; 76:41–50

6) Kim JYS, et al. J Am Acad Dermatol. 2018; 78:540–59

7) Odomzo (sonidegib) [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; 2017

8) European Medicines Agency. Summary of Product Characteristics, WC500188762

9) Swissmedic, Authorization Number 65065, 2015

10) Australian Government Department of Health, ARTG 292262

11) Migden MR, et al. Lancet Oncol. 2015; 16:716–28

12) Migden MR, et al. J Clin Oncol. 2018; 36:Suppl abstr 9551

13) Lear JT, et al. J Eur Acad Dermatol Venereol. 2018; 32:372–81

14) Dummer R, et al. J Am Acad Dermatol

Most read articles by the same author(s)